What is “Givlaari”?
Givlaari is a brand name for givosiran, a medicine used to treat acute hepatic porphyria (AHP), specifically to reduce attacks in people with acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP). [1]
How does Givlaari work?
Givosiran is designed to lower levels of a key liver enzyme (ALAS1) that drives overproduction of porphyrin precursors linked to AHP attacks. Lowering those upstream signals can reduce the frequency of acute attacks. [1]
How is Givlaari given?
Givlaari (givosiran) is administered as an injection (subcutaneous). [1]
Who is it for?
Givlaari is intended for people with acute hepatic porphyria who experience recurrent attacks. [1]
What side effects do people ask about?
Commonly reported side effects include injection-site reactions and liver-related lab changes (tests that reflect liver function). [1]
How long does treatment take to show effects?
For medicines like givosiran, the clinical goal is to reduce attack frequency over time, with effects assessed during treatment cycles. Exact timelines can vary by person. [1]
What should I check with a clinician before starting?
Patients typically review:
- baseline and follow-up liver tests
- suitability for ongoing AHP attack prevention
- any history of liver problems or other major medical conditions relevant to dosing and monitoring [1]
Sources
[1] https://www.givlaari.com/ (official Givlaari site; product information)